gilteritinib
2215-CL-0201
Phase 3 small_molecule completed
Quick answer
gilteritinib for Acute Myeloid Leukemia (AML) is a Phase 3 program (small_molecule) at Astellas Pharma Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Astellas Pharma Inc
- Indication
- Acute Myeloid Leukemia (AML)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed